To assess the role of BCL9 in promotion of DCIS invasive progression, two shRNA-based BCL9 constructs have been utilized: shRNA1 [11] and shRNA2, as well as their corresponding scrambled controls (Control 1 and Control 2). The gene discussed is BCL9; the disease is ductal breast carcinoma in situ.